vs
Side-by-side financial comparison of Orchestra BioMed Holdings, Inc. (OBIO) and Stevanato Group S.p.A. (STVN). Click either name above to swap in a different company.
Orchestra BioMed Holdings, Inc. is a clinical-stage medical technology company focused on developing novel, evidence-based therapeutic solutions for cardiovascular and other high-burden chronic diseases. It collaborates with leading healthcare stakeholders, operates primarily across North American and European markets, with core segments covering interventional cardiology and chronic disease care optimization.
Stevanato Group is an Italian multinational company headquartered in Piombino Dese, Padua – Italy. Founded in 1949, it is also active in the glass tube forming technology and inspection systems sector.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.9M | — | ||
| Q3 25 | $861.0K | — | ||
| Q2 25 | $836.0K | — | ||
| Q1 25 | $868.0K | — | ||
| Q4 24 | $253.0K | — | ||
| Q3 24 | $987.0K | — | ||
| Q2 24 | $778.0K | — | ||
| Q1 24 | $620.0K | — |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $-20.8M | — | ||
| Q2 25 | $-19.4M | — | ||
| Q1 25 | $-18.8M | — | ||
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $-15.4M | — | ||
| Q2 24 | $-16.0M | — | ||
| Q1 24 | $-13.5M | — |
| Q4 25 | 99.8% | — | ||
| Q3 25 | 94.3% | — | ||
| Q2 25 | 94.5% | — | ||
| Q1 25 | 94.9% | — | ||
| Q4 24 | 77.1% | — | ||
| Q3 24 | 93.1% | — | ||
| Q2 24 | 94.3% | — | ||
| Q1 24 | 94.5% | — |
| Q4 25 | 21.8% | — | ||
| Q3 25 | -2359.2% | — | ||
| Q2 25 | -2311.8% | — | ||
| Q1 25 | -2179.8% | — | ||
| Q4 24 | -6591.7% | — | ||
| Q3 24 | -1655.7% | — | ||
| Q2 24 | -2167.0% | — | ||
| Q1 24 | -2326.3% | — |
| Q4 25 | 20.2% | — | ||
| Q3 25 | -2419.0% | — | ||
| Q2 25 | -2316.1% | — | ||
| Q1 25 | -2160.7% | — | ||
| Q4 24 | -6385.4% | — | ||
| Q3 24 | -1562.9% | — | ||
| Q2 24 | -2054.0% | — | ||
| Q1 24 | -2171.5% | — |
| Q4 25 | $0.28 | — | ||
| Q3 25 | $-0.40 | — | ||
| Q2 25 | $-0.50 | — | ||
| Q1 25 | $-0.49 | — | ||
| Q4 24 | $-0.42 | — | ||
| Q3 24 | $-0.41 | — | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.38 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
